TELA Bio (TELA) Cash & Equivalents (2018 - 2026)

TELA Bio has reported Cash & Equivalents for 9 years, with the latest figure at $39.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 7.69% year-over-year to $39.5 million; the trailing twelve-month figure through Mar 2026 stood at $39.5 million (down 7.69% YoY), and the FY2025 full-year result was $50.8 million, down 3.46% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $39.5 million, down from $50.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $65.3 million in Q2 2023, with the low at $17.3 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $40.5 million, with a median of $39.5 million recorded in 2026.
• Year-over-year, Cash & Equivalents surged 135.4% in 2023 and slumped 70.27% in 2024.
• Tracing TELA's Cash & Equivalents over 5 years: stood at $42.0 million in 2022, then advanced by 11.21% to $46.7 million in 2023, then gained by 12.71% to $52.7 million in 2024, then fell by 3.46% to $50.8 million in 2025, then declined by 22.23% to $39.5 million in 2026.
• The last three Cash & Equivalents figures came in at $39.5 million (Q1 2026), $50.8 million (Q4 2025), and $29.7 million (Q3 2025), per Business Quant data.

Peer Comparison